• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Chiron Recombinant Proteins

    CMC Pharmaceuticals

    LOTTE BIOLOGICS

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Chiron Recombinant Proteins

    CMC Pharmaceuticals

    LOTTE BIOLOGICS

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Aspargo Laboratories Completes Pre-IND Meeting with FDA

    Collaborating with the CDMO Pii to develop and manufacture Sildenafil Oral Spray for clinical trials

    Related CONTENT
    • Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
    • First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    • J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax
    • Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention
    • Asychem Partners with LaNova Medicines
    Contract Pharma Staff06.08.20
    Aspargo Laboratories Inc., a privately held, clinical stage pharmaceutical company, has announced the results of its pre-Investigational New Drug (pre-IND) meeting with the FDA, where the FDA addressed Aspargo’s questions and provided guidance on the company’s Sildenafil Oral Spray for the treatment of erectile dysfunction (ED).
     
    The FDA was supportive of a single dose bioequivalent study comparing Aspargo’s Sildenafil Oral Spray, an oral liquid suspension formulation of sildenafil citrate, with Viagra tablets and deemed the 505(b)(2) regulatory pathway appropriate for the program.
     
    “We are encouraged by the outcome of the pre-IND meeting with the FDA and based on their feedback are advancing towards an IND submission for Sildenafil Oral Spray in the third quarter of 2020,” said Michael Demurjian, CEO of Aspargo. “Importantly, the FDA deemed the 505(b)(2) regulatory pathway appropriate for our clinical program and pending results from our planned single-dose bioequivalent study, we do not foresee the need to conduct any additional long-term safety, toxicology or phase 3 efficacy studies. We look forward to advancing Sildenafil Oral Spray in the U.S. market to provide men who suffer from erectile dysfunction a differentiated dosing formulation that provides convenient administration, flexible dosing and access for  ED patients who have difficulty swallowing oral tablets.”
     
    In its written response, the FDA supported Aspargo’s plan to conduct a single dose bioequivalent study to evaluate the pharmacokinetics, bioequivalency, tolerability and safety of the company’s Sildenafil Oral Spray drug candidate, administered via a metered dose pump or individual single liquid unit, when compared to Viagra tablets. The randomized, single center, unblinded, three-way crossover study will seek to enroll a total of 72 healthy volunteers who will receive a single dose of Sildenafil Oral Spray administered via a dose metered pump, a single dose of Sildenafil Oral Spray administered via an individual single liquid unit or a single dose of Viagra oral tablet. Thirty-six subjects will be treated under fed conditions and thirty-six subjects will be treated under fasting conditions. 
     
    The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of clinical trials.
     
    Aspargo is collaborating with Pharmaceutics International Inc. (Pii), a CDMO located in Hunt Valley, MD, to develop and manufacture Sildenafil Oral Spray for clinical trials.  Pii is also laying the groundwork for the future commercial manufacturing requirements of Sildenafil Oral Spray in the U.S.
    Suggested For You
    Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients  Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax
    Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention
    Asychem Partners with LaNova Medicines Asychem Partners with LaNova Medicines
    BioVaxys Reports Progress on Covid-19 Vax Candidate BioVaxys Reports Progress on Covid-19 Vax Candidate
    Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals
    U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
    U.S. Govt. Purchases Additional Doses of Lilly U.S. Govt. Purchases Additional Doses of Lilly's Antibody Therapies for COVID
    Aurion Biotech Makes Strategic Investments in Manufacturing Aurion Biotech Makes Strategic Investments in Manufacturing
    Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies
    Boyds Opens US Office in PA Boyds Opens US Office in PA
    COVID Booster Vaccines: What’s Next for FDA COVID Booster Vaccines: What’s Next for FDA
    Repligen and Navigo Launch Antibody Technology Platform Repligen and Navigo Launch Antibody Technology Platform
    Trust, but Verify Trust, but Verify

    Related Breaking News

    • Breaking News | Drug Development | Industry News
      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization.
      09.22.21

    • Breaking News | Clinical Trials
      First Patient is Dosed with Triumvira

      First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy

      TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.
      09.21.21

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax

      J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax

      Phase 3 ENSEMBLE trial shows booster shot at two months provided 94 percent protection against COVID-19 in the U.S.
      09.21.21


    • Breaking News | Industry News
      Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention

      Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention

      Phase 3 study shows bamlanivimab 4200 mg reduced the risk of contracting symptomatic COVID-19 by up to 80 percent in nursing home residents.
      09.17.21

    • Breaking News | Collaborations & Alliances | Industry News
      Asychem Partners with LaNova Medicines

      Asychem Partners with LaNova Medicines

      Will provide one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
      09.16.21

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Multi-Strain Probiotic Improves Self-Reported Mood, Sleep, Serotonin Levels
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login